A Review of Mechanisms of Disease Across PIK3CA-related Disorders with Vascular Manifestations

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2021 Jul 9

PMID 34238334

Citations 48

Authors

Guillaume Canaud

Adrienne M Hammill

Denise Adams

Miikka Vikkula

Kim M Keppler-Noreuil

Affiliations

Soon will be listed here.

Abstract

Background: PIK3CA-related disorders include vascular malformations and overgrowth of various tissues that are caused by postzygotic, somatic variants in the gene encoding phosphatidylinositol-3-kinase (PI3K) catalytic subunit alpha. These mutations result in activation of the PI3K/AKT/mTOR signaling pathway. The goals of this review are to provide education on the underlying mechanism of disease for this group of rare conditions and to summarize recent advancements in the understanding of, as well as current and emerging treatment options for PIK3CA-related disorders.

Main Body: PIK3CA-related disorders include PIK3CA-related overgrowth spectrum (PROS), PIK3CA-related vascular malformations, and PIK3CA-related nonvascular lesions. Somatic activating mutations (predominantly in hotspots in the helical and kinase domains of PIK3CA, but also in other domains), lead to hyperactivation of the PI3K signaling pathway, which results in abnormal tissue growth. Diagnosis is complicated by the variability and overlap in phenotypes associated with PIK3CA-related disorders and should be performed by clinicians with the required expertise along with coordinated care from a multidisciplinary team. Although tissue mosaicism presents challenges for confirmation of PIK3CA mutations, next-generation sequencing and tissue selection have improved detection. Clinical improvement, radiological response, and patient-reported outcomes are typically used to assess treatment response in clinical studies of patients with PIK3CA-related disorders, but objective assessment of treatment response is difficult using imaging (due to the heterogeneous nature of these disorders, superimposed upon patient growth and development). Despite their limitations, patient-reported outcome tools may be best suited to gauge patient improvement. New therapeutic options are needed to provide an alternative or supplement to standard approaches such as surgery and sclerotherapy. Currently, there are no systemic agents that have regulatory approval for these disorders, but the mTOR inhibitor sirolimus has been used for several years in clinical trials and off label to address symptoms. There are also other agents under investigation for PIK3CA-related disorders that act as inhibitors to target different components of the PI3K signaling pathway including AKT (miransertib) and PI3K alpha (alpelisib).

Conclusion: Management of patients with PIK3CA-related disorders requires a multidisciplinary approach. Further results from ongoing clinical studies of agents targeting the PI3K pathway are highly anticipated.

Citing Articles

Phosphoinositide Metabolism: Biochemistry, Physiology and Genetic Disorders.

Rossignol F, Lamari F, Mitchell G J Inherit Metab Dis. 2025; 48(2):e70008.

PMID: 40024625 PMC: 11872349. DOI: 10.1002/jimd.70008.

Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital.

El Sissy F, Bisdorff A, Perrier A, Guillerm E, Denis J, Favre L Mol Diagn Ther. 2025; .

PMID: 39899252 DOI: 10.1007/s40291-025-00770-0.

Uncovering somatic mosaic variants of -related overgrowth disorders - three cases with different clinical presentations.

Tooming M, Mertsina P, Kahre T, Teek R, Vainumae I, Lilles S Front Genet. 2025; 15:1484651.

PMID: 39872006 PMC: 11769973. DOI: 10.3389/fgene.2024.1484651.

Comisi F, Soddu C, Lai F, Marica M, Lorrai M, Mancuso G Pediatr Rep. 2024; 16(4):1200-1206.

PMID: 39728742 PMC: 11677636. DOI: 10.3390/pediatric16040101.

Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR.

Bosselmann C, Leu C, Brunger T, Hoffmann L, Baldassari S, Chipaux M Nat Commun. 2024; 15(1):10429.

PMID: 39616148 PMC: 11608322. DOI: 10.1038/s41467-024-54911-w.

References

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Keppler-Noreuil K, Parker V, Darling T, Martinez-Agosto J . Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet. 2016; 172(4):402-421. PMC: 5592089. DOI: 10.1002/ajmg.c.31531. View

Van Damme A, Seront E, Dekeuleneer V, Boon L, Vikkula M . New and Emerging Targeted Therapies for Vascular Malformations. Am J Clin Dermatol. 2020; 21(5):657-668. DOI: 10.1007/s40257-020-00528-w. View

Lopez Gutierrez J, Lizarraga R, Delgado C, Martinez Urrutia M, Diaz M, Miguel M . Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome. J Pediatr Adolesc Gynecol. 2019; 32(6):648-650. DOI: 10.1016/j.jpag.2019.07.003. View

Piacitelli A, Jensen D, Brandling-Bennett H, Gray M, Batra M, Gust J . Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients. Am J Med Genet A. 2018; 176(11):2301-2308. PMC: 6290925. DOI: 10.1002/ajmg.a.40487. View

Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken J . Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2008; 41(1):118-24. PMC: 2670982. DOI: 10.1038/ng.272. View

Kuentz P, St-Onge J, Duffourd Y, Courcet J, Carmignac V, Jouan T . Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med. 2017; 19(9):989-997. DOI: 10.1038/gim.2016.220. View

Dekeuleneer V, Seront E, Van Damme A, Boon L, Vikkula M . Theranostic Advances in Vascular Malformations. J Invest Dermatol. 2020; 140(4):756-763. DOI: 10.1016/j.jid.2019.10.001. View

Lokhorst M, Horbach S, van der Horst C, Spuls P . Finalizing the international core domain set for peripheral vascular malformations: the OVAMA project. Br J Dermatol. 2019; 181(5):1076-1078. PMC: 6900166. DOI: 10.1111/bjd.18043. View

10.

Mirzaa G, Timms A, Conti V, Boyle E, Girisha K, Martin B . -associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight. 2016; 1(9). PMC: 5019182. DOI: 10.1172/jci.insight.87623. View

11.

Garneau A, Haydock L, Tremblay L, Isenring P . Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America. J Mol Med (Berl). 2021; 99(3):311-313. PMC: 7900069. DOI: 10.1007/s00109-020-02030-6. View

12.

Lokhorst M, Horbach S, Waner M, O T, van der Vleuten C, Spuls P . Responsiveness of quality of life measures in children with peripheral vascular malformations: The OVAMA project. JPRAS Open. 2020; 27:70-79. PMC: 7753079. DOI: 10.1016/j.jpra.2020.11.013. View

13.

Rossler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M . Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. Pediatr Blood Cancer. 2021; 68(8):e28936. DOI: 10.1002/pbc.28936. View

14.

Chacon-Camacho O, Lopez-Moreno D, Morales-Sanchez M, Hofmann E, Pacheco-Quito M, Wieland I . Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies. Mol Genet Genomic Med. 2019; 7(5):e625. PMC: 6503218. DOI: 10.1002/mgg3.625. View

15.

Ranieri C, Di Tommaso S, Loconte D, Grossi V, Sanese P, Bagnulo R . In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics. 2018; 19(2):77-91. PMC: 5956072. DOI: 10.1007/s10048-018-0540-1. View

16.

Limaye N, Boon L, Vikkula M . From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet. 2009; 18(R1):R65-74. PMC: 2657941. DOI: 10.1093/hmg/ddp002. View

17.

Mirzaa G, Conway R, Gripp K, Lerman-Sagie T, Siegel D, deVries L . Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet A. 2012; 158A(2):269-91. DOI: 10.1002/ajmg.a.34402. View

18.

Horbach S, van der Horst C, Blei F, van der Vleuten C, Frieden I, Richter G . Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. Br J Dermatol. 2017; 178(2):473-481. DOI: 10.1111/bjd.16029. View

19.

Erickson J, McAuliffe W, Blennerhassett L, Halbert A . Fibroadipose vascular anomaly treated with sirolimus: Successful outcome in two patients. Pediatr Dermatol. 2017; 34(6):e317-e320. DOI: 10.1111/pde.13260. View

20.

Martinez-Corral I, Zhang Y, Petkova M, Ortsater H, Sjoberg S, Castillo S . Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation. Nat Commun. 2020; 11(1):2869. PMC: 7280302. DOI: 10.1038/s41467-020-16496-y. View